A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

Inclusion Criteria

• •Men and women diagnosed with stable plaque psoriasis with involvement of the palm(s)and/or sole(s) for at least 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator.
• •Moderate-to-severe plaque psoriasis defined as s-PGA score of ≥ 3 on a 5-point scale at both screening visit and Day 1.
• •Moderate-to-severe non-pustular PP psoriasis, defined as pp-PGA score of ≥ 3 on a 5-pointscale and pp-PASI ≥ 8 at both screening visit and Day 1.
• •* A total maximum of 5 sterile pustules across both palms and soles limited only to psoriatic plaques will be allowed.
• •Evidence of typical plaque psoriasis outside palms and soles at both screening visit and Day 1.
• •Deemed by the investigator to be a candidate for phototherapy or systemic therapy.
• •Failed to respond to, or intolerant of ≥ 1 topical therapy.
• •Men and women diagnosed with stable plaque psoriasis with involvement of the genital area for at least 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator.
• •Moderate-to-severe plaque psoriasis defined as s-PGA score of ≥ 3 on a 5-point scale at both screening visit and Day 1.
• •Moderate-to-severe GenPs, defined as static Physician's Global Assessment of Genitalia (s-PGA-G) score of ≥ 3 on a 6-point scale at both screening visit and Day 1.
• •Evidence of typical plaque psoriasis in a non-genital area at both screening visit and Day 1.
• •Deemed by the investigator to be a candidate for phototherapy or systemic therapy.
• •Failed to respond to, or intolerant of ≥ 1 topical therapy.